Elisa Manzotti

Learn More
Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disease with thrombotic predilection resulting in vascular thrombotic events and obstetric complications. Management of APS focuses on anticoagulation; however, despite the solid evidence suggesting that this is the best treatment option available, a lot of debate persists regarding the(More)
Today, we have a global healthcare industry dependant upon three main pillars: pharmaceuticals, biopharmaceuticals and medical devices. To this list will soon be added a fourth and equally important new pillar, the cell therapy industry. Whilst presently small in overall size and poorly defined in composition, it is none the less universally recognized as(More)
Future Medicine Ltd, Unitec House, 2 Albert Place, Finchley Central, London, N3 1QB, UK Tel.: +44 208 371 6090 Fax: +44 208 343 2313 e.manzotti@ futuremedicine.com www.futuremedicine.com 2010 marks the 25th anniversary of the cell therapy industry with the founding in 1985 of the first companies in the sector including Celox, Creative Biomolecules and(More)